Riding the wave, The world's first acute myocardial infarction antibody SGC001 of Sungen Biomedical was presented at U.S. J.P. Morgan Conference
On January 12th, the 43rd Annual J.P. Morgan Healthcare Conference (JPM Conference), an influential investment seminar, took place in San Francisco. Sungen Biomedical made a notable presentation featu...
About Us
Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Sci-Tech innovation board...
First in the World! Sungen Biomedical Obtains FDA's Clinical Trial Approval of IND SGC001 as An Emergency-use Antibody Drug for AMI
First in the world! Sungen Biomedical obtains FDA's clinical trial approval of IND SGC001 as an emergency-use antibody drug for AMIOn May 23rd, 2024, Eastern Standard Time, US Food and Drug Administr...
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
On March 17, 2025, US time, the world’s first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hot...
